Eli Lilly’s experimental weight loss pill, orforglipron, may soon shift the landscape of obesity treatment. In a Phase 3 clinical trial that spanned more than 3,000 adults, the once-daily pill helped participants lose an average of 12.4% of their body weight over 72 weeks—with minimal lifestyle restrictions and no needles involved.

The company says these findings mark a turning point in the battle against obesity, one of the most pressing global health issues today. Here’s how this oral medication is poised to change everything we know about weight loss treatment.

According to Eli Lilly’s preliminary data, adults who took the highest dose of orforglipron lost an average of 27.3 pounds (12.4% of their body weight) over roughly a year and a half. Nearly 60% of those participants lost at least 10% of their weight, and almost 40% lost at least 15%.

These results are on par with injectable GLP-1 medications like Zepbound and Mounjaro—both also made by Eli Lilly—which have become blockbuster drugs in the obesity and diabetes market.

Dr. Céline Gounder, editor-at-large for public health at KFF Health News, put it bluntly in a CBS interview: “This is what we see with injectables. It’s impressive that a pill could match that.”

The key distinction? Orforglipron is not a peptide-based medication. That makes it easier for the body to absorb and eliminates the need for the strict dietary rules that apply to oral peptide drugs like Novo Nordisk’s Rybelsus.

How GLP-1 in Pill Form Works?

Orforglipron belongs to a class of medications called GLP-1 receptor agonists. These drugs mimic a gut hormone that plays a critical role in appetite regulation and glucose metabolism. They slow down stomach emptying, curb hunger signals in the brain, and help stabilize blood sugar levels.

Until recently, the most effective GLP-1 medications had to be injected, often weekly. Eli Lilly’s innovation—compressing this powerful mechanism into an oral pill—is a major step forward.

Unlike Rybelsus, the only approved GLP-1 pill on the market (which requires fasting and water restrictions), orforglipron is designed to be taken at any time of day, with or without food or water. That alone could make a big difference for patient compliance and everyday ease of use.

Are There Significant Side Effects For This Pill?

The benefits are clear, but what about the risks? As with other GLP-1-based drugs, gastrointestinal side effects were common. The most reported issues included nausea, diarrhea, constipation, and vomiting. Between 29% and 34% of participants experienced nausea—slightly higher than the 25–29% range seen with injectable Zepbound.

More significantly, about 10% of those on the highest dose had to drop out of the study due to side effects. While not uncommon in drug trials, it’s a notable figure for clinicians to weigh when considering patient suitability.

Still, experts say the side effect profile remains consistent with what is expected from GLP-1 medications. Importantly, orforglipron was also associated with improved markers of cardiovascular health, such as lower cholesterol and blood pressure.

What Makes Orforglipron Stand Out?

One of the most promising aspects of this pill is its potential to support long-term weight maintenance. Eli Lilly is also studying orforglipron’s role in helping people who initially lose weight on injectable drugs but are looking for a more manageable, sustainable option moving forward.

In essence, this pill could serve as a bridge—or even an off-ramp—for those who can’t or don’t want to stay on injectable medications forever. The convenience factor is huge.

There’s also the question of cost. Manufacturing pills is typically cheaper than producing injectables, and while pricing hasn’t been announced yet, orforglipron could offer a more affordable option for millions of people who need access to effective obesity care.

Eli Lilly has announced plans to submit orforglipron for regulatory approval by the end of 2025, with hopes of a global launch to follow soon after. If approved by the FDA and other agencies, the drug could hit the market in 2026.

This timeline is aggressive but realistic, given the urgency of the obesity crisis. More than 40% of American adults are classified as obese, according to CDC data. The economic burden and health consequences—including increased risk of heart disease, stroke, diabetes, and certain cancers—are staggering.

The public health need is urgent, and the demand for safe, convenient, and effective weight-loss treatments is at an all-time high. A pill like orforglipron, if approved, could help close that gap.

Despite the promising clinical data, not everyone is convinced just yet. Eli Lilly’s stock fell nearly 14% on the day of the announcement. Some investors expected even greater weight-loss figures or a better side effect profile.

But experts caution against reading too much into the stock market’s knee-jerk reactions. The potential of a widely accessible, non-peptide, once-daily GLP-1 pill is enormous—and it could spark a new era in weight management.

If successful, orforglipron will likely intensify the competition with Novo Nordisk, whose Wegovy and Ozempic have dominated the obesity and diabetes space for the past few years. The race is now on for the first truly scalable, cost-effective oral GLP-1 option—and Lilly may have just edged ahead.

Eli Lilly’s orforglipron isn’t just another weight-loss drug. It’s a potential paradigm shift in how we approach chronic weight management.

If it clears the final regulatory hurdles and delivers on its early promise, orforglipron could bring highly effective, user-friendly weight-loss treatment to millions of people—no needles, no meal timing, no fuss. That’s the kind of change the obesity crisis has been waiting for.

Diabetes patients rely upon metformin for controlling their blood sugar and insulin levels. Now, a new study claims that this common diabetes drug has many other health benefits to offer, and these can mimic the benefits of 'intense workouts.' The diabetes drug metformin is used by millions around the world who are struggling with this lifestyle disorder—it releases weight-regulating compounds in the body, the same ones that are released during workouts in inactive people. American scientists found that the drug can have a positive impact on a sedentary lifestyle—find out how.

What is metformin?

Metformin is the most common drug for the management of type 2 diabetes. It helps insulin work better, thereby regulating blood sugar spikes. This drug is usually prescribed when diet and workouts alone are not sufficient for weight management. According to a study by experts at the University of Miami Miller School of Medicine’s Sylvester Comprehensive Cancer Center, metformin may replicate the benefits of workouts in people who follow a sedentary, inactive lifestyle. In the case of prostate cancer patients, men who do not work out because of their treatment benefited from metformin use, as the drug raises levels of a molecule that supports weight loss. In the case of patients who cannot work out properly, the effect can be game-changing.

Are workouts necessary during cancer treatment?

Exercising is one of the best ways to avoid obesity and other metabolic disorders. It is also one of the best ways to stay strong during cancer treatment, as it regulates weight, heart health, and blood sugar. This helps cancer patients feel stronger even during treatment and recovery. However, many cancer patients cannot work out regularly because of hormone therapy-related fatigue. Metformin use, in this case, can prove helpful for patients.

How does metformin mimic the benefits of workouts?

Exercising benefits the body by releasing hormones such as oxytocin and dopamine. Researchers from the Sylvester Comprehensive Cancer Center explored whether these could be triggered without exercise and whether metformin could do that. They noted that while the drug cannot fully replace workouts as part of a healthy routine, there is a need to understand how a widely used drug can be beneficial for metabolic health during prostate cancer treatment.

N-lactoyl-phenylalanine, or Lac-Phe, is a molecule that spikes after an intense workout session, and it also regulates appetite and calorie burning. Scientists found that Lac-Phe levels were higher in metformin users even when they were not working out. The Sylvester team noted that prostate cancer patients often struggle with poor blood sugar control, heart disease risk, and weight gain due to hormone therapy. They then took blood samples from 29 people and found that the patients who took metformin had similar Lac-Phe levels to people who were engaged in strenuous workouts. This was noted even when the patients were not exercising. However, metformin did not have an impact on prostate tumours.

The study was published in the EMBO Molecular Medicine journal.

In an alarming incident, more than 330 children in Pakistan have contracted HIV due to reuse of syringes in a hospital in Pakistan’s Punjab, according to a report.

The report, based on an undercover investigation by BBC News, highlighted blatant infection control failures and unsafe medical practices at THQ Hospital Taunsa in Pakistan.

The failures captured on camera, filmed over 32 hours inside THQ Taunsa Hospital in late 2025, showcase persistent unsafe practices, including the reuse of syringes on multi-dose vials, that have infected more than 330 children with HIV since late 2024.

The footage captured multiple violations of basic hygiene protocols, including the staff reusing syringes on multi-dose medicine vials, which increases the risk of contaminating entire batches of medication. In several instances, the same vial was then used to treat different children, the report said.

Other scenes captured included poor sanitation conditions, such as open vials, used needles left on countertops, and improper disposal of medical waste; staff administering injections without sterile gloves, further increasing the risk of cross-contamination.

Pakistan HIV Cases: Previous Outbreak In Southern Sindh

The incident in Taunsa is not the first. In 2019, media reports cited nearly 1,000 children testing positive for HIV due to the reuse of needles in southern Sindh province.

“Pakistan has experienced a series of HIV outbreaks over the past two decades, but we’ve never before seen this many young children infected or so many health facilities involved," Dr Fatima Mir from the Aga Khan University in Pakistan, told The Guardian. She was the lead author of the paper published in the Lancet Infectious Diseases, which also reported the cases.

“Use of syringes and needles is widespread, and Pakistan has one of the highest rates of unsafe injections in the world. Health practitioners need to use intravenous treatment only when necessary, use needles only once, and screen blood for infections before using it for transfusions,” she added.

The India Case: Thalassemic Children Infected With HIV

In 2025, a dozen children undergoing blood transfusions for thalassemia contracted HIV in two different incidents in India's Madhya Pradesh and Jharkhand, highlighting “systemic lapses in blood bank regulations”.

At least six children were found HIV positive at Satna district hospital in Madhya Pradesh, allegedly due to contaminated blood transfusions at the district hospital during treatment for thalassemia.

The children affected include five boys aged under 11 and a nine-year-old girl who have been undergoing blood transfusions at the hospital.

Another six children with thalassemia reportedly contracted HIV from contaminated blood transfusions at a government hospital in the West Singhbhum district of Jharkhand.

Safe Injection Practices: What Is Recommended

The World Health Organization (WHO) mandates the use of single-use, safety-engineered syringes—specifically auto-disable (AD) or reuse-prevention (RUP) devices—to prevent disease transmission and needle-stick injuries.

These devices automatically lock or break after one use and are essential for immunization and medication administration.

The US CDC recommends using single-dose vials whenever possible, over multiple-dose vials, especially when medications will be administered to multiple patients.

Do not administer medications from a syringe to multiple patients, even if the needle or cannula on the syringe is changed.

The US Food and Drug Administration has recalled China-made over-the-counter cough drops and throat lozenges sold across the country over potential safety concerns.

The FDA in a notice stated that Xiamen Kang Zhongyuan Biotechnology from Xiamen in China, has issued a voluntary recall of numerous products based on March 20, 2026.

The regulator noted that the recall was started following the FDA’s recommendation based on observations noted during an August 15, 2025, inspection of the manufacturing facility that “may bear on product quality.”

The FDA classified the recall as Class II on April 10, 2026. Class II recalls apply to products that can cause “temporary or medically reversible” health problems.

While the FDA did not specify how many cough drops were under the recall, the recalled products include:

• Exchange Select (manufactured for Your Military Exchanges): 30-count bag of honey lemon and menthol flavored cough drops
• Caring Mill (distributed by FSA Store, Inc): 90-count bags of cherry cough drops
• Discount Drug Mart Food Market: 30-count bags of honey lemon cough drops
• MGC Health (distributed by Medical Group Care): 25-count and 30-count bags of sugar-free honey lemon cough drops and 80-count bags of honey lemon cough drops
• QC Quality Choice (distributed by CDMA, Inc): 25-count bags of black cherry sugar-free and regular cough drops; 25-count bags of sugar-free and regular honey lemon cough drops; 30-count bags of creamy strawberry throat soothing drops; 30-count bags of menthol cough drops; and 30-count bags of vanilla honey cough drops.

Safe Alternatives For Cough Drops

Coughs are often caused by viral infections, allergies, or environmental irritants such as dust or smoke.

Also read: Eye Drops: US FDA Recalls Over 3 Million Products Over Safety Concerns

Dr. Umashankar Sharma, Medical In-charge (B.N.Y.S), Kailash Institute of Naturopathy, Ayurveda & Yoga, recommends several safe home remedies that can ease both adults' and children’s discomfort naturally.

“Warm liquids like soups, clear broths, or mild herbal teas, such as chamomile, help keep the throat moist and reduce irritation. Honey is a great natural option for children over one year; half to one teaspoon before bedtime can help calm night-time coughing,” he said.

He also suggests using a cool-mist humidifier in the room to add moisture to the air, which can loosen mucus and ease breathing. Saline nasal drops or a short steam session in a warm shower can also help relieve congestion.

Ensuring plenty of rest and hydration with water or warm drinks is essential. Slightly elevating the head with an extra pillow at night can reduce coughing while sleeping.

These remedies are generally safe and effective. However, if the cough persists for more than two weeks, or if the individual experiences high fever, wheezing, or difficulty breathing, it’s important to consult a doctor to rule out more serious conditions.

Home Remedies For Sore Throat

According to the Centers for Disease Control and Prevention, throat pain linked to an upper respiratory infection usually improves within about a week. Over-the-counter pain relievers like ibuprofen or naproxen can help ease discomfort and may be more effective than acetaminophen because they reduce both pain and inflammation.

Alongside medication, certain home remedies may also provide relief. Options worth trying include saltwater gargle, honey and herbal tea, or other hot beverages such as soups.